While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

The global autologous cell therapy market, valued at USD 10.12 billion in 2024, is poised for remarkable expansion, reaching a projected valuation of USD 44.55 billion by 2033. This growth, driven by ...

Could you provide a simple explanation of CAR T-cell therapy, highlighting the key differences between autologous and allogeneic approaches? CAR T-cell therapy is really an exciting treatment for ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...